SI-BONE Inc

SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 2008 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SI-BONE reports record Q4 revenue, eyes global growth opportunities

SI-BONE's Q4 2022 performance reflects robust revenue growth and operational improvements, driven by increased surgeon engagement and product adoption.
The company's financial stability, strong cash position, and strategic focus on growth opportunities position it well for future success and market expansion.
While facing challenges such as undisclosed study enrollment and international growth pacing, SI-BONE's focus on operational efficiency and market opportunities presents a positive outlook for sustained growth and profitability.

SI-BONE Inc reports robust Q1 revenue growth and raises 2023 guidance

SI-BONE Inc had a strong Q1 performance with robust revenue growth and surgeon adoption. While facing some challenges with expense increases, the company is optimistic about future growth opportunities and aims for improved financial performance throughout 2023.

SI-BONE Inc reports robust Q2 growth and optimistic outlook

SI-BONE Inc's Q2 2023 showcased strong revenue growth, improved operational efficiency, and enhanced cash position.
Company's product portfolio, FDA clearances, and revenue guidance revisions underscore its growth potential and market competitiveness.
Challenges include managing increased operating expenses, evolving marketing strategies, and maintaining growth momentum.
Opportunities lie in expanding surgeon base, leveraging training programs, conducting market studies, and aiming for a strong second half performance.

SI-BONE reports record revenue in Q3 2023, eyes market expansion

SI-BONE's Q3 2023 earnings call showcased robust financial performance, strong market positioning, and growth prospects. With record revenue, increased guidance, and a focus on innovation and market expansion, SI-BONE is well-positioned for continued success in the medical device industry.

SI-BONE reports record revenue growth and strategic product launches

SI-BONE Inc delivered strong financial performance in Q4 2023, with record revenue, improved EBITDA, and a solid cash position for future growth initiatives.
The company's strategic strengths lie in its U.S. market dominance, innovative product launches, and positive revenue guidance for 2024.
Challenges include expanding international revenue, pricing competitiveness, and effective training for new products, while opportunities exist in market expansion and product innovation.
Overall, SI-BONE's performance highlights its resilience, growth potential, and strategic focus on driving innovation and market expansion in the medical device sector.

SI-BONE Inc reports robust Q1 revenue growth and strategic focus

SI-BONE Inc's Q1 performance reflects strong revenue growth and operational achievements, underpinned by strategic priorities and market differentiation. While facing challenges in expense management and profitability, the company is well-positioned to capitalize on opportunities through innovation and market disruption.

SI-BONE Inc reports strong Q2 earnings, eyes growth opportunities

SI-BONE Inc delivered robust financial performance in Q2 2024, driven by revenue growth, increased active physicians, and improved EBITDA.
The company's strengths lie in customer loyalty, innovation, leadership enhancements, and a clear path to financial sustainability.
Challenges include operational scalability, sustaining revenue growth, balancing innovation with cost control, and effective Board integration.
Opportunities for SI-BONE include accelerating revenue growth, expanding into new market segments, diversifying product offerings, and leveraging strategic Board additions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

SANTA CLARA, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2023 after market close on Monday, August 7, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023

Greenbrier Companies

NCR Corporation

NCR, GBX and SIBN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 6, 2023.

Best Momentum Stocks to Buy for July 6th

AvidXchange Holdings

Griffon

GBX, GFF, AVDX, NCR and SIBN have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2023.

New Strong Buy Stocks for July 6th

SI-BONE is pushing higher in revenues and gross profit, clipping another strong quarter. It pulled in 80% gross margin and expects this on a revised FY'23 outlook. Additional fundamental catalysts are the revised Granite segment outlook and increase in surgeon engagement.

SI-BONE: Rating Higher On Fundamental, Economic Grounds

SANTA CLARA, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2023 Jefferies Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, June 7th, 2023, at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time.

SI-BONE To Present at Jefferies 2023 Healthcare Conference on June 7, 2023

SANTA CLARA, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the pricing of its underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $22.00. Of the shares of common stock being offered, 3,502,247 shares are being offered by SI-BONE and 272,753 shares are being offered by a selling stockholder. In addition, SI-BONE has granted the underwriters a 30-day option to purchase up to an additional 566,250 shares of the company's common stock on the same terms and conditions. Gross proceeds to SI-BONE from the offering are expected to be approximately $77.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. SI-BONE will not receive any proceeds from the sale of the shares of common stock by the selling stockholder in the offering. The offering is scheduled to close on May 9, 2023, subject to the satisfaction of customary closing conditions.

SI-BONE Announces Pricing of Public Offering of Common Stock

SANTA CLARA, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that it has commenced an underwritten public offering of 3,775,000 shares of its common stock. Of the shares of common stock being offered, 3,502,247 shares are being offered by SI-BONE and 272,753 shares are being offered by a selling stockholder. In addition, SI-BONE expects to grant the underwriters a 30-day option to purchase up to an additional 566,250 shares of the company's common stock on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

SI-BONE Announces Launch of Public Offering of Common Stock

Si-Bone (SIBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Si-Bone (SIBN) Upgraded to Buy: Here's What You Should Know

Si-Bone makes the iFuse Implant System for the sacroiliac joint, found in the lower back. The company said it increased its surgeon base to 950 surgeons in the U.S. Revenue for Si-Bone was up 46% year over year.

Why Shares of Si-Bone Jumped Tuesday

SI-BONE, Inc. (NASDAQ:SIBN ) Q1 2023 Earnings Conference Call May 1, 2023 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Drew Ranieri - Morgan Stanley Young Li - Jefferies Sam Brodovsky - Truist Dave Turkaly - JMP Securities Kyle Rose - Canaccord Ross Osborn - Cantor Fitzgerald David Saxon - Needham & Company Operator Good afternoon, and welcome to SI-BONE's First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

SI-BONE, Inc. (SIBN) Q1 2023 Earnings Call Transcript

Annual guidance increased to $128 million - $131 million, implying annual growth of 20%-23% Annual guidance increased to $128 million - $131 million, implying annual growth of 20%-23%

SI-BONE, Inc. Reports Financial Results for the First Quarter 2023 and Increases Annual Guidance

SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2023 Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 9th, 2023, at 1:55 p.m. Eastern Time / 10:55 a.m. Pacific Time.

SI-BONE to Present at Bank of America Merrill Lynch 2023 Global Healthcare Conference

SANTA CLARA, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2023 after market close on Monday, May 1, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report First Quarter 2023 Financial Results on May 1, 2023

SI-BONE, Inc. (NASDAQ:SIBN ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Saqib Iqbal - Director of Investor Relations Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord David Rescott - Truist Securities Craig Bijou - Bank of America Ross Osborn - Cantor Fitzgerald Dave Turkaly - JMP Securities Drew Ranieri - Morgan Stanley David Saxon - Needham & Company Operator Good afternoon, and welcome to SI-BONE's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

SI-BONE, Inc. (SIBN) Q4 2022 Earnings Call Transcript

Si-Bone (SIBN) delivered earnings and revenue surprises of 23.81% and 0.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

SANTA CLARA, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2022.

SI-BONE, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Issues 2023 Guidance

SANTA CLARA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the fourth quarter of 2022 after market close on Monday, February 27, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SI-BONE To Report Fourth Quarter 2022 Financial Results on February 27, 2023

Fourth Quarter revenue of $31.7 - $31.9 million representing growth of approximately 26% Fiscal Year 2022 revenue of $106.1 - $106.3 million representing growth of approximately 18%

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2022

SANTA CLARA, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 25th Annual Needham Growth Conference. Management will be hosting a virtual fireside chat on Thursday, January 12th, 2023, at 11:45 a.m. Eastern Time / 8:45 a.m. Pacific Time.

SI-BONE to Host a Virtual Fireside Chat at the 25th Annual Needham Growth Conference

SI-BONE, Inc. presents as a niche operator in the surgical intervention of sacroiliac disorders. There are multiple inflection points on the horizon for SI-BONE in FY 2023.

SI-BONE: Multiple Inflection Points On The Horizon In FY 2023

New Indications Include Use with a Broad Class of Commercially Available Rods New Indications Include Use with a Broad Class of Commercially Available Rods

SI-BONE, Inc. Announces FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite® Implant System

SI-BONE, Inc. (NASDAQ:SIBN ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group Laura Francis - Chief Executive Officer Anshul Maheshwari - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord Craig Bijou - Bank of America David Rescott - Truist Securities Andrew Ranieri - Morgan Stanley David Turkaly - JMP Securities Ross Osborn - Cantor Fitzgerald Young Li - Jefferies David Saxon - Needham & Company Operator Good afternoon, and welcome to SI-BONE's Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode.

SI-BONE, Inc. (SIBN) CEO Laura Francis on Q3 2022 Results - Earnings Call Transcript

Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2022.

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2022 and Updates Guidance

Si-Bone (SIBN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for SI-BONE Inc Stock (SIBN)